APA (7th ed.) Citation

Xia Luo, Zhen Zhou, Xiaohui Zeng, Liubao Peng, & Qiao Liu. (2022). Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China. Frontiers Media S.A..

Chicago Style (17th ed.) Citation

Xia Luo, Zhen Zhou, Xiaohui Zeng, Liubao Peng, and Qiao Liu. Cost-effectiveness of Ensartinib, Crizotinib, Ceritinib, Alectinib, Brigatinib and Lorlatinib in Patients with Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer in China. Frontiers Media S.A., 2022.

MLA (9th ed.) Citation

Xia Luo, et al. Cost-effectiveness of Ensartinib, Crizotinib, Ceritinib, Alectinib, Brigatinib and Lorlatinib in Patients with Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer in China. Frontiers Media S.A., 2022.